PHILADELPHIA--(EON: Enhanced Online News)--A cascade of bombshell bench decisions, a Presidential veto, new legislation and landmark patent deals continues to change the face of the Intellectual property (IP) world as the Licensing Executives Society (U.S.A. and Canada), Inc. prepares to host its Annual Meeting, September 22-25 in Philadelphia. The expert-driven program, themed ‘IP Matters in Every Deal,’ is designed to help licensing, IP and business development professionals in all sectors navigate the changing landscape, with newly-added Hot Topic sessions covering late-breaking industry developments.
NEWLY-ADDED HOT TOPIC SESSIONS
Congress vs. Trolls: Big Implications for Licensing and the Future of Innovation: Leaders from the high technology industry, life sciences and academia will discuss the various pending “anti-troll” bills. Although the bills vary in their approaches, enactment of any one of them would have a profound and lasting affect on the licensing industry and innovation in general. Attendees will hear what unintended consequences are likely and discuss what leaders should do about it. On the same theme, the meeting will also feature To Troll or Not to Troll? Legislative, Judicial and Market-Based Solutions, an all-star IP executive debate on the role of patent assertion entities and other developments that could affect the ability to license IP in the future.
How to Determine What’s “Reasonable” in RAND Royalty Rates: Former Federal Trade Commission (FTC) and International Trade Commission (ITC) leaders will join representatives from ktMine to offer analysis and guidance on implications of the U.S. District Court for the Western District of Washington’s recently established framework for determining reasonable and non discriminatory (“RAND”) royalty rates on standard-essential patents (“SEPs”), which was constructed using a hypothetical negotiation between Motorola and Microsoft and has modified the Georgia Pacific Factors.
What You Haven’t Been Told About Licensing Standard-Essential Patents (SEP): The Patent Holder’s Perspective will offer a corporate perspective on several recent rulings related to SEP licensing and what the future holds in light of recent court decisions, a Presidential veto at the ITC and the Apple v Samsung case. The panel will be led by the Senior Vice President and General Manager for Qualcomm Technology Licensing, Qualcomm Inc.
OTHER NEWLY-ADDED SESSIONS:
- The Increasing Importance of Trade Secrets in Intellectual Property Portfolio Management in an Uncertain Patent Landscape features corporate IP leaders from ConocoPhillips, BP America, Velocys and Nixon Peabody who will discuss the increasing importance of trade secrets in IP portfolios and licensing strategies in light of recent Supreme Court case law, as well as lessons learned and useful strategies for maintaining trade secrets.
- Biotechnology Innovations after Myriad and Prometheus will explore implications of the Supreme Court ruling on chemical and pharma patents directed toward naturally occurring compounds and will offer guidance for seeking such patents. The meeting will also feature a keynote address from Myriad Genetics General Counsel, Richard Marsh who will touch on the Supreme Court ruling, as well as offer insights on the company’s evolution from start up to leader in the diagnostic market.
- When Bad Things Happen to Good Deals will include Vice President and Senior Counsel for IP Transactions, Kodak; Manager of IP & Licensing, ExxonMobil Upstream Research Company; and, Global Managing Director, DuPont (invited) who will consider a fictitious technology licensing case study to explore the profound impact of words, clauses and phrases when it comes to “living with the deal.”
- Patent Issues in the Cloud Service and Storage Industry will feature a thorough exploration of this timely issue by the Chief Executive Officer of Unified Patents; Senior Patent Counsel, Google; and Chair of IP and Technology Transactions Group and Green Tech and Sustainability Group, Kaye Scholer.
- Brand and Trademark Role in Licensing Deals: Licensing Tools and Tactics to Enforce Your IP and Avoid Litigation will feature the Senior Director, Business Development, Johnson & Johnson Consumer Companies, Inc.; Managing Director and Chairman, IMC; and Managing Director of F T I Consulting.
In addition, the year’s top IP deals will receive 2013 Deals of Distinction™ Awards. Representatives from the winning deal teams, including Battelle, Celgene and Epizyme, will discuss deal evolution and lessons learned along with an exclusive briefing with architects of the $527 million Kodak deal.
The meeting is expected to draw nearly 1,000 of the world’s leading IP, licensing and business development professionals from top companies, research institutions, government labs and other technology-oriented organizations including AstraZeneca, Blackberry, Canon, Celgene, DuPont, FTC, GE, Gilead, Intel, John Deere, Kimberly Clark, Merck, Microsoft, National Institutes of Health, Roche, Shell, Takeda and others.
Click here to view the full program, virtual offerings, speakers, registration and more.